Roche holders tender $1.04 billion of two note series by early deadline

By Susanna Moon

Chicago, Nov. 13 – Roche Holdings, Inc. gave the early tender results of the offer to purchase up to $2.2 billion of two note series.

As of 5 p.m. ET on Nov. 12, the early tender date, investors had tendered the following amounts, listed in order of priority acceptance level:

• $149,834,000 of Genentech, Inc.’s $500 million of 5.25% senior notes due 2035; and

• $893,925,000 of Roche Holdings, Inc.’s $2.5 billion of 7% notes due 2039, guaranteed by Roche Holding Ltd.

The total purchase price for each $1,000 principal amount will be $1,196.42 for the 5.25% notes and $1,456.92 for the 7% notes.

The total payment includes a $50.00 early tender premium per $1,000 of notes tendered by the early deadline.

Those who tender after the early deadline will receive the total amount less the early tender premium.

The tender offer will end at 11:59 p.m. ET on Nov. 26. Tendered notes may no longer be withdrawn, as of the early deadline.

J.P. Morgan Securities LLC (liability management group, at 800 834-4666 or 212 834-4811 collect) is the dealer manager. D.F. King & Co., Inc. (800 761-6521 or 212 269-5550 collect or email roche@dfking.com) is the information agent and tender agent.

Roche is a Basel, Switzerland-based drug maker.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.